• Medison’s campaign created unanimous consent that an immediate
  change is required at Knight and also a collective demand from
  shareholders that Knight’s leadership create near term value and
  increase the share price
• Medison’s campaign “rocked the boat” and made Knight leadership
  commit to implementing required changes that can increase the share
  price
• Medison nominee Kevin Cameron, together with new independent
  nominee Michael Tremblay, are elected to Knight Board of Directors and
  will assist in remedying governance deficiencies and conflicts of
  interest exposed by Medison campaign
• Meir Jakobsohn decided to withdraw his nomination from the board,
  believes he can be more effective operating from the outside as an
  active shareholder
• Medison respects shareholders’ vote not to adopt the Diamond
  Strategy, and pledges to pursue it independent of Knight

PETACH TIKVA, Israel–(BUSINESS WIRE)–Medison Biotech (1995) Ltd. (“Medison”), which together with its
affiliates owns more than 10.4 million shares or 7.3% of Knight
Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”),
today issued the following statement from Medison CEO Meir Jakobsohn on
Knight’s 2019 Annual Meeting of Shareholders:

Our campaign created unanimous consent that an immediate change is
required at Knight and also a collective demand from shareholders that
Knight’s leadership create near term value and increase the share price.

Our campaign “rocked the boat” and made Knight’s leadership commit to
implementing required changes that can increase the share price.

Medison nominee, Kevin Cameron, together with new independent nominee
Michael Tremblay, have been elected to Knight Board of Directors and
will assist in remedying governance deficiencies and conflicts of
interest exposed by Medison’s campaign.

I would like to note that I decided to withdraw my nomination for the
board, as I believe I can be more effective operating from the outside
as an active shareholder.

We respect the shareholder vote not to adopt the Diamond Strategy,
and Medison pledges to pursue it independent of Knight.

To all our fellow Knight shareholders, Medison intends to maintain an
open dialogue with you and will continue to highlight key findings and
perspectives as appropriate.

I personally thank each shareholder on your engagement in open
discussions with us, on being open and transparent even when we had
different views on some matters, and on being able to disregard
misinformation and distractions and focus on the real issues at hand,
which we face together as shareholders of Knight.

Medison will maintain its website www.NewDayForKnight.com and
shareholders are encouraged to visit it for updates.

About Medison

Medison is one of the world’s largest commercial partners of leading
global biotech companies. Backed by three generations of experience in
the healthcare industry since 1937, Medison is uniquely qualified to
provide the complete spectrum of integrated services for international
companies looking to enter or expand their presence in Israeli and
selected ROW markets. Over the years, Medison has become the partner of
choice for biotech companies that produce highly innovative, cutting
edge therapeutics for commercialization in the Israeli market and is
currently the second largest pharmaceutical company in Israel, with over
CAD 250 million in revenues annually and over 270 employees. Medison
runs a corporate venture arm with a dedicated research and evaluation
team boasting deep scientific and commercial backgrounds. Medison also
operates a scouting program to cater to its partners and is an active
investor in life science projects around drug development and digital
health.

Contacts

Media
Gagnier Communications
Dan Gagnier, 646-569-5897
[email protected]